Catalyst Pharmaceuticals, Inc.:
Firdapse approved in Nov 2018 for Lambert-Eaton Myasthenic Syndrome (LEMS) - 2 positive Ph 3s complete, potential launch early '19. Addl ongoing trials in congenital myasthenic syndromes (CMS), MuSK myasthenia gravis & Spinal Muscular Atrophy Type 3.
Phase III, Registration Stage
Central Nervous System, Rare Disease
100MM - 500MM
355 Alhambra Circle
Coral Gables, FL 33134
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Clients at Jefferies
New York, NY, United States,
June 4 –
June 7, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by